Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003.

Purpose: We hypothesized that bevacizumab will potentiate activity of pembrolizumab. We conducted a phase Ib/II, single-arm, multisite clinical trial of the combination in metastatic renal cell carcinoma (RCC).Patients and Methods: Patients with metastatic clear cell RCC who experienced progression...

Full description

Bibliographic Details

Published in:	Journal of Clinical Oncology Vol. 38; no. 11; pp. 1138 - 1147
Main Authors:	Dudek, Arkadiusz Z., Liu, Li C., Gupta, Shilpa, Logan, Theodore F., Singer, Eric A., Joshi, Monika, Zakharia, Yousef N., Lang, Joshua M., Schwarz, James K., Al-Janadi, Anas, Alva, Ajjai S.
Format:	research Journal Article
Published:	American Society of Clinical Oncology 4/10/2020
Online Access:	View this record in EBSCOhost